GO:0016362 activin receptor activity, type II: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016362 (activin receptor activity, type II) is a molecular function defined as combining with activin to initiate a change in cell activity; upon ligand binding, the receptor binds to and catalyses the phosphorylation of a type I activin receptor [QuickGO].
• Type II activin receptors are serine/threonine kinases that act as the primary ligand-binding subunits of the activin receptor complex and trans-phosphorylate type I receptors such as ALK4, ALK5, and ALK7.
• The pathway is a major regulator of skeletal muscle mass, cardiac aging, and heart failure, making it a high-value therapeutic target [1,2,3,4].
• Blockade of activin type II receptors with antibodies or ligand traps preserves muscle mass and enhances fat loss during GLP-1 receptor agonism [3,7].
• Activin E signals specifically through ALK7, illustrating ligand-specific utilization of type II receptor complexes.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential for dissecting type II activin receptor signaling in disease [1,6].
Description
GO:0016362, activin receptor activity, type II, is a molecular function that describes the ability of a type II activin receptor to bind activin and, upon ligand binding, to phosphorylate a type I activin receptor, thereby initiating intracellular signaling [QuickGO]. This activity is the first committed step in activin signal transduction and is central to the regulation of cell growth, differentiation, and tissue homeostasis. The type II receptor is a transmembrane serine/threonine kinase that serves as the ligand-binding subunit of the activin receptor complex, while the type I receptor acts as the downstream kinase that propagates the signal to SMAD proteins. Research over the past two decades has established that activin type II receptor signaling is a critical node in skeletal muscle wasting, cardiac aging, and metabolic disease. For example, activin type II receptor signaling has been shown to drive cardiac aging and heart failure, and its blockade improves cardiac function in preclinical models. In skeletal muscle, antibody-mediated blockade of activin type II receptors preserves muscle mass and enhances fat loss during GLP-1 receptor agonism. These findings have propelled type II activin receptors into clinical development, including bimagrumab, an investigational human monoclonal antibody against activin type II receptors for treating obesity. Despite this progress, the precise molecular mechanisms, ligand specificity, and context-dependent roles of type II activin receptors remain active areas of investigation. Recent work has shown that activin E signals specifically through activin receptor-like kinase 7, highlighting the complexity of ligand-receptor pairing. In addition, blockade of activin receptor type IIA/IIB increases muscle mass and strength but compromises glycemic control in mice, underscoring the need for careful mechanistic dissection. This article provides a research-grade overview of GO:0016362, covering its definition, mechanism, key genes, disease relevance, and the CRISPR-based methods used to study it.
activin receptor activity, type II At A Glance
| GO ID | GO:0016362 |
|---|---|
| GO term | activin receptor activity, type II |
| Ontology | molecular_function |
| Synonym | type II activin receptor activity |
| Definition | Combining with activin to initiate a change in cell activity; upon ligand binding, binds to and catalyses the phosphorylation of a type I activin receptor. |
| Major function | Ligand-binding and type I receptor phosphorylation in activin signaling |
| Receptor class | Transmembrane serine/threonine kinase |
| Ligands | Activin A, activin B, activin E, and related TGF-beta superfamily ligands |
| Downstream targets | Type I receptors ALK4, ALK5, ALK7; SMAD2/3 signaling |
What Is GO:0016362?
In our own words, GO:0016362 (activin receptor activity, type II) is the molecular function of a cell-surface receptor that binds activin ligands and, once bound, phosphorylates a type I activin receptor. This phosphorylation event is the critical switch that converts an extracellular activin signal into an intracellular response, typically through SMAD-dependent transcription. The term is specific to the type II receptor subunit, distinguishing it from type I receptor activity and from other TGF-beta family receptor functions [QuickGO].
Why Is activin receptor activity, type II Important in Cell Biology?
GO:0016362 is important because it represents the primary molecular event through which activin and related ligands control muscle mass, cardiac function, and metabolism. Dysregulation of this activity contributes to muscle wasting, heart failure, and metabolic disease, and therapeutic blockade of type II activin receptors is now in clinical trials for obesity and muscle-related conditions [1,2,3,4]. Understanding this activity at the molecular level is therefore essential for developing targeted interventions.
• Controls skeletal muscle mass and strength through regulation of protein synthesis and degradation [3,4].
• Drives cardiac aging and heart failure progression, and its blockade improves cardiac outcomes in models.
• Is a validated therapeutic target for obesity and muscle loss, with antibodies such as bimagrumab in development.
• Mediates the effects of GDF8 and activin A on muscle, and blockade protects against GLP-1-induced muscle loss.
• Shows ligand-specific signaling, as activin E signals specifically through ALK7.
• Is inhibited by small molecules such as SB-431542, which blocks type I ALK receptors downstream of type II activity.
• Is implicated in pulmonary hypertension through ALK2 regulation in vascular smooth muscle cells.
• Provides a molecular entry point for CRISPR-based functional genomics of TGF-beta superfamily signaling.
Molecular Mechanism of activin receptor activity, type II
Ligand binding and receptor complex assembly
In simple terms: First, activin grabs onto the type II receptor, which then recruits a type I receptor to form a signaling pair.
The type II activin receptor is a transmembrane serine/threonine kinase that serves as the primary ligand-binding subunit. Upon binding activin, the type II receptor undergoes conformational changes that allow it to recruit and associate with a type I receptor, such as ALK4, ALK5, or ALK7. This assembly is the first committed step in activin signaling and is required for downstream phosphorylation events.
Trans-phosphorylation of the type I receptor
In simple terms: The type II receptor then acts like a kinase switch, adding phosphate groups to the type I receptor to turn it on.
Once the ligand-receptor complex is formed, the constitutively active type II receptor kinase phosphorylates the GS domain of the type I receptor. This phosphorylation activates the type I receptor kinase, which then propagates the signal to SMAD proteins. The type II receptor thus functions as the catalytic subunit that initiates the phosphorylation cascade.
Downstream SMAD activation and transcriptional regulation
In simple terms: The activated type I receptor then passes the signal to SMAD proteins, which move to the nucleus and change gene expression.
Phosphorylated type I receptors activate SMAD2 and SMAD3, which form complexes with SMAD4 and translocate to the nucleus to regulate transcription of target genes. This pathway controls genes involved in muscle growth, fibrosis, and metabolism. The specificity of downstream responses can be influenced by the type I receptor utilized, as shown by activin E signaling specifically through ALK7.
Regulation by inhibitors and ligand traps
In simple terms: This activity can be blocked by small molecules or antibody traps that prevent the receptor from signaling.
Small-molecule inhibitors such as SB-431542 block type I ALK receptors (ALK4, ALK5, ALK7) and thereby inhibit signaling downstream of type II receptor activity. Antibody-based blockade of type II activin receptors, such as bimagrumab, prevents ligand binding and inhibits downstream signaling, leading to increased muscle mass and fat loss [2,3]. These tools are essential for dissecting the pathway.
Context-dependent roles in cardiac and metabolic tissues
In simple terms: The same receptor activity can have different effects depending on the tissue, such as heart or muscle.
In cardiac tissue, activin type II receptor signaling contributes to aging and heart failure, and its blockade improves cardiac function. In skeletal muscle, blockade increases mass and strength but may compromise glycemic control, indicating tissue-specific outcomes. In vascular smooth muscle cells, ALK2 regulation by BRCC3 implicates type II receptor signaling in pulmonary hypertension.
Key Genes Involved in GO:0016362 activin receptor activity, type II
The following genes and proteins are central to the study of GO:0016362 and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ACVR2A | Type II activin receptor A; binds activin and phosphorylates type I receptors | Target for muscle wasting and cardiac disease [1,3] |
| ACVR2B | Type II activin receptor B; mediates activin and myostatin signaling | Antibody target for obesity and muscle preservation [2,3] |
| ACVR1B (ALK4) | Type I receptor phosphorylated by type II receptors | Downstream effector in activin signaling |
| ACVR1C (ALK7) | Type I receptor for activin E and other ligands | Ligand-specific signaling node |
| TGFBR1 (ALK5) | Type I receptor in TGF-beta/activin signaling | Inhibitor target SB-431542 |
| INHBA | Activin A subunit; ligand for type II receptors | Ligand in muscle and metabolic studies |
| INHBB | Activin B subunit; ligand for type II receptors | Ligand in reproductive and metabolic biology |
| INHBE | Activin E subunit; signals through ALK7 | Ligand-specific pathway |
| MSTN | Myostatin; related TGF-beta ligand | Muscle mass regulation |
| SMAD2 | Downstream transcription factor | Mediates activin signaling |
| SMAD3 | Downstream transcription factor | Mediates activin signaling |
| SMAD4 | Co-SMAD; forms complexes with SMAD2/3 | Transcriptional regulation |
| BRCC3 | Regulates ALK2 in vascular smooth muscle cells | Pulmonary hypertension |
| FKBP12 | Binds and inhibits type I receptors | Regulation of receptor activity |
| Bimagrumab target | Monoclonal antibody against type II receptors | Clinical obesity trials |
| GDF8 | Myostatin; ligand for type II receptors | Muscle wasting |
How Is activin receptor activity, type II Regulated?
The activity of type II activin receptors is regulated at multiple levels. Ligand availability is controlled by secreted antagonists such as follistatin and by proteolytic processing of pro-ligands. At the receptor level, the type II receptor kinase is constitutively active, but its ability to phosphorylate type I receptors depends on ligand-induced complex assembly. Intracellular inhibitors such as FKBP12 can bind type I receptors and prevent phosphorylation. Additionally, small-molecule inhibitors like SB-431542 block type I receptor kinases downstream of type II activity, providing pharmacological control. Antibody-based blockade of type II receptors prevents ligand binding and downstream signaling, as demonstrated by bimagrumab and related antibodies [2,3,7].
activin receptor activity, type II and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ACVR2A | Cardiac aging and heart failure | Cardiac-specific knockout mouse |
| ACVR2B | Muscle wasting and obesity | Antibody-treated obese mouse [2,3] |
| ACVR1C (ALK7) | Metabolic and reproductive disorders | ALK7 knockout mouse |
| BRCC3 | Pulmonary hypertension | Vascular smooth muscle cell knockout |
| INHBA | Muscle loss and metabolic disease | Ligand trap or knockout mouse |
Cardiac aging and heart failure
Activin type II receptor signaling is activated in the aging heart and contributes to heart failure. Blockade of this pathway improves cardiac function and reduces fibrosis in preclinical models, suggesting that GO:0016362 is a therapeutic target for cardiac disease.
Skeletal muscle wasting and obesity
Type II activin receptor signaling promotes muscle atrophy and limits fat loss. Antibody blockade of these receptors preserves muscle mass and enhances fat loss during GLP-1 receptor agonism, and bimagrumab is being investigated for obesity treatment [2,3,7]. However, blockade may compromise glycemic control, highlighting the need for careful patient selection.
Pulmonary hypertension
In vascular smooth muscle cells, BRCC3 regulates ALK2, a type I receptor downstream of type II activin receptor activity. Dysregulation of this axis contributes to pulmonary hypertension, linking GO:0016362 to vascular disease.
Metabolic and reproductive disorders
Activin E signals specifically through ALK7, a type I receptor activated by type II receptors, and is implicated in metabolic and reproductive biology. This ligand-specific signaling expands the disease relevance of GO:0016362 beyond muscle and heart.
From activin receptor activity, type II-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of type II receptor activity increase muscle mass? | ACVR2A/ACVR2B double knockout mouse |
| Does type II receptor blockade improve cardiac function? | Cardiac-specific inducible knockout or antibody treatment |
| Which type I receptor mediates activin E signaling? | ALK7 knockout or point-mutation knock-in |
| Can type II receptor blockade preserve muscle during GLP-1 therapy? | Obese mouse treated with GLP-1 agonist and anti-ACVR2 antibody |
| What is the role of BRCC3 in ALK2 regulation? | Vascular smooth muscle cell-specific knockout |
| Does type II receptor activity regulate glycemic control? | Inducible whole-body knockout with metabolic phenotyping |
How to Study the activin receptor activity, type II Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effects on signaling | Identify essential genes in activin pathway [1,4] |
| Phospho-Western blot | Type I receptor and SMAD phosphorylation | Measure receptor activity |
| RNA-seq | Transcriptional changes | Define downstream gene programs [1,3] |
| Surface plasmon resonance | Ligand-receptor binding affinity | Characterize antibody blockade |
| Immunohistochemistry | Tissue localization of receptors | Assess expression in muscle and heart [1,6] |
| Metabolic phenotyping | Glycemic control and body composition | Evaluate therapeutic blockade |
| CRISPR activation (CRISPRa) | Overexpression of pathway genes | Gain-of-function studies |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify genes that modulate type II activin receptor signaling. For example, knocking out ACVR2A or ACVR2B in muscle precursor cells followed by activin treatment and readout of SMAD phosphorylation can reveal pathway components [1,4].
Phospho-proteomics and Western blotting
Phosphorylation of type I receptors and SMAD2/3 is a direct readout of type II receptor activity. Phospho-specific antibodies and mass spectrometry-based phosphoproteomics can quantify these events in cells treated with activin or inhibitors.
Transcriptomics and RNA-seq
RNA sequencing of cells or tissues with manipulated type II receptor activity can identify downstream transcriptional programs. This is particularly useful for understanding tissue-specific effects, such as in muscle or heart [1,3].
Ligand-binding assays and surface plasmon resonance
Direct measurement of activin binding to type II receptors can be performed using radiolabeled ligands or surface plasmon resonance. These assays are used to characterize antibody blockade and ligand specificity [2,8].
How CRISPR Can Be Used to Study GO:0016362 activin receptor activity, type II
Knockout
CRISPR knockout of ACVR2A or ACVR2B in cell lines or animal models abolishes type II receptor activity, leading to loss of SMAD phosphorylation and downstream transcriptional responses. This approach has been used to demonstrate the role of these receptors in muscle mass and cardiac function [1,4].
Point Mutation
Point mutations in the kinase domain of ACVR2A or ACVR2B can be introduced to dissect catalytic activity versus ligand binding. For example, kinase-dead mutants can be generated to determine whether phosphorylation of type I receptors is required for specific downstream effects.
Knock-in
Knock-in of epitope tags or fluorescent reporters into the endogenous ACVR2A or ACVR2B locus allows real-time tracking of receptor expression and localization. This is useful for studying receptor trafficking and complex assembly.
Overexpression
Overexpression of wild-type or mutant type II receptors in cell lines can amplify signaling and enable biochemical studies of receptor phosphorylation and downstream activation. This approach is often used in combination with inhibitor treatments [5,8].
How EDITGENE Supports activin receptor activity, type II Research
Researchers studying activin receptor activity, type II-related genes often need to determine whether a candidate gene is causally involved in signaling, disease progression, or therapeutic response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of GO:0016362 and its associated pathways.
Contact EDITGENE today to design your custom CRISPR model for activin receptor activity, type II research.
Frequently Asked Questions About activin receptor activity, type II
What is activin receptor activity, type II?
It is a molecular function (GO:0016362) where a type II activin receptor binds activin and phosphorylates a type I activin receptor, initiating intracellular signaling [QuickGO].
What genes are involved in activin receptor activity, type II?
Key genes include ACVR2A, ACVR2B, ACVR1B (ALK4), ACVR1C (ALK7), TGFBR1 (ALK5), and ligands such as INHBA, INHBB, and INHBE [5,8].
What diseases are associated with type II activin receptor signaling?
It is linked to cardiac aging, heart failure, muscle wasting, obesity, and pulmonary hypertension [1,2,3,4,6].
How is type II activin receptor activity regulated?
It is regulated by ligand availability, receptor complex assembly, intracellular inhibitors like FKBP12, and pharmacological inhibitors such as SB-431542.
What is the role of ACVR2B in muscle mass?
ACVR2B mediates activin and myostatin signaling to limit muscle growth; its blockade increases muscle mass and enhances fat loss [2,3,7].
Can CRISPR be used to study type II activin receptors?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect receptor function [1,4,6].
What is bimagrumab?
Bimagrumab is an investigational monoclonal antibody against activin type II receptors being studied for obesity and muscle-related conditions.
How does activin E signal?
Activin E signals specifically through the type I receptor ALK7, which is activated by type II receptors.
What are the downstream effectors of type II activin receptor activity?
The main downstream effectors are SMAD2 and SMAD3, which form complexes with SMAD4 and regulate transcription.
What methods are used to measure type II activin receptor activity?
Common methods include phospho-Western blotting, RNA-seq, surface plasmon resonance, and CRISPR screens [1,3,5].
Conclusion
GO:0016362, activin receptor activity, type II, is a central molecular function in TGF-beta superfamily signaling that controls muscle mass, cardiac function, and metabolism. Its dysregulation contributes to heart failure, muscle wasting, and metabolic disease, and therapeutic blockade of type II receptors is a promising strategy [1,2,3,4]. Continued research using CRISPR-based models will further elucidate the precise mechanisms and context-dependent roles of this activity. EDITGENE provides end-to-end CRISPR services, from knockout and knock-in models to library screening and bioinformatics, to accelerate discovery in activin receptor biology and therapeutic development.
References
- 1. Roh JD et al.. 2019. Activin type II receptor signaling in cardiac aging and heart failure.. Sci Transl Med 11(482) PMID: 30842316
- 2. Kaur M et al.. 2024. Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity.. J Basic Clin Physiol Pharmacol 35(6):325-334 PMID: 39385353
- 3. Nunn E et al.. 2024. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.. Mol Metab 80:101880 PMID: 38218536
- 4. Carlsson M et al.. 2025. Activin receptor type IIA/IIB blockade increases muscle mass and strength, but compromises glycemic control in mice.. Mol Metab 102:102261 PMID: 41022302
- 5. Inman GJ et al.. 2002. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.. Mol Pharmacol 62(1):65-74 PMID: 12065756
- 6. Shen H et al.. 2024. BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.. Circulation 150(2):132-150 PMID: 38557054
- 7. Mastaitis JW et al.. 2025. GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates.. Nat Commun 16(1):4377 PMID: 40360507
- 8. Vestal KA et al.. 2024. Activin E is a transforming growth factor β ligand that signals specifically through activin receptor-like kinase 7.. Biochem J 481(7):547-564 PMID: 38533769
